{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-004446","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.673819+00:00","generated_at":"2026-06-07T02:16:44.762067+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Guardant Health reports preliminary 2023 revenue ~$562-563M (+25% YoY); clinical test volumes up 39%","bullets":["Full year 2023 revenue $562-563M, up 25% YoY; clinical test volume 172,900 (+39%).","Q4 2023 revenue $153-154M (+21%); clinical tests 46,400 (+29%).","Full year free cash flow approx. -$347M; cash and equivalents $1.2B as of Dec 31, 2023.","Co-CEOs cite Shield blood test progress; expect FDA approval and IVD launch in 2024.","Results are preliminary and unaudited; final audited results expected in February 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-004446","json":"https://secwatch.observer/filing/0001193125-24-004446.json","markdown":"https://secwatch.observer/filing/0001193125-24-004446.md","text":"https://secwatch.observer/filing/0001193125-24-004446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000119312524004446/0001193125-24-004446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000119312524004446/d710991d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:16:44.762067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ac0117949fce72cb0e26437a0c2e77dd693e8e8","claim":"Guardant Health, Inc. reported the twelve-month period ended December 31, 2023 results: revenue $562 million and $563 million.","evidence_excerpt":"Full year 2023 preliminary unaudited financial results For the twelve-month period ended December 31, 2023, as compared to the same period of 2022: • Revenue of between $562 million and $563 million, an increase of 25%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000119312524004446/0001193125-24-004446-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the twelve-month period ended December 31, 2023"},{"label":"Revenue","value":"$562 million and $563 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"6b2a9651b6aabe3aa1f337f5638e9328f07ef930","claim":"Guardant Health, Inc. reported the three-month period ended December 31, 2023 results: revenue $153 million and $154 million.","evidence_excerpt":"Fourth quarter 2023 preliminary unaudited financial results For the three-month period ended December 31, 2023, as compared to the same period of 2022: • Revenue of between $153 million and $154 million, an increase of 21%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000119312524004446/0001193125-24-004446-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three-month period ended December 31, 2023"},{"label":"Revenue","value":"$153 million and $154 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}